Currently Viewing:
Newsroom
Currently Reading
Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women
May 17, 2018 – Jaime Rosenberg
USPSTF Recommends Patient Choice for Prostate Cancer Screening
May 10, 2018 – Jaime Rosenberg
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 09, 2018 – Samantha DiGrande
This Week in Managed Care: May 4, 2018
May 04, 2018
AJMC® in the Press, May 4, 2018
May 04, 2018 – AJMC Staff
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 02, 2018 – Jaime Rosenberg
What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits
May 02, 2018 – AJMC Staff
FDA, FTC Warn 13 Firms for Selling Vaping Juice With Kid-Friendly Appeal
May 01, 2018 – Allison Inserro
FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC
April 30, 2018 – Jaime Rosenberg

Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women

Jaime Rosenberg
While immune checkpoint inhibitors significantly improve overall survival in both sexes, the magnitude of benefit is dependent on sex, according to new study findings.
A patient’s sex might play a role in how they respond to immunotherapy, according to new study findings.

Noting differences in the immune system between men and women, researchers hypothesized that these differences could be relevant to conditions such as cancer, as well as their reaction to therapies. Men have an almost 2-times higher risk of mortality from all cancers, which is likely to reflect differences not only in behavioral and biological factors, but also in the immune system, according to the authors of the study.

“Cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed death receptor-1 (PD-1) pathways play an important role in tumor-induced immunosuppression, and they are increasingly being exploited as therapeutic targets in several types of advanced malignancies,” wrote the authors. “Sex hormones regulate the expression and function of PD-1 and PD-L1, and the hormonal effects on the PD-1 pathway are important in mediating autoimmunity.”

The study, published in Lancet Oncology, combined data from 20 previously published randomized trials including 11,351 patients who received immune checkpoint inhibitors—ipilimumab, tremelimumab, nivolumab, or pembrolizumab—for advanced metastatic cancers. Of the patients, 7646 (67%) were male and 3705 (33%) were female.

When compared with control cohorts, the authors observed a significant difference in the efficacy of immune checkpoint inhibitors between the men and women. Male patients treated with immune checkpoint inhibitors as monotherapy or as combination therapy had a significantly reduced risk of mortality compared with men treated in the control cohorts (pooled overall survival HR 0.72, 95% CI 0.65-0.79). For female patients, the benefits yielded from the immune checkpoint inhibitors compared with the control cohorts was smaller, in comparison (HR 0.86, 95% CI, 0.79-0.93).

The higher survival benefit for men was seen regardless of cancer type or drug administered, and, on average, the relative survival gain was double the size for men.

The authors did note that in small-cell lung cancer, the addition of ipilimumab to standard chemotherapy was not effective in improving overall survival for both men and women.

“Despite the obvious biological and physiological differences between men and women, and the extensive literature on the potential role played by sex in influencing drug pharmacokinetics, pharmacodynamics, and efficacy, new therapeutic approaches are rarely tested taking sex into account,” explained the authors.

They argued that patients’ sex should be taken into account in the assessment of risk versus benefit as an important variable in predicting the relative benefit of immunotherapy drugs compared with available standard therapies. While checkpoint inhibitors significantly improve overall survival in both sexes, the magnitude of benefit is dependent on sex.

Taking these results into account, the authors also urged that future research focus on improving outcomes for women, such as exploring different immunotherapeutic approaches in men and women. They concluded by recommending that researchers conducting immunotherapy studies should ensure a larger inclusion of women in the trials.

Reference:

Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. [published online May 16, 2018]. Lancet Oncol. doi: https://doi.org/10.1016/S1470-2045(18)30261-4. 

Related Articles

Clinical Perspectives in the Evolving Role of Immuno-Oncology Treatment With Jason J. Luke, MD, FACP
PFS Recommended as Primary End Point for Phase 2 Immune Checkpoint Inhibitor Trials
Oncologists Must Weigh Risks, Benefits of Immune Checkpoint Inhibitors
Future Shock: Embracing Disruption in the Immunotherapy Revolution
Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up